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Summary: Educational reforms over a century ago established a the-
ory to practice undergraduate medical curriculum design, in which 
“theory” equated with biomedical science. It is remarkable that a 
theory of professional knowledge that is so old has been so little 
challenged. We continue to assume that mastery of a rather limited 
canon of knowledge will lead inductively to practical competence and 
are surprised and disappointed when it does not. Donald Schön has 
written about the tension between the “high ground” of the universi-
ties and the “swampy lowlands” of practice. Gradually, the swampy 
lowlands have gained scholarly credibility, and a tension is becoming 
apparent between the competence that is needed to be an effective 
practitioner and the competencies that are taught in universities. 
Yet, there is a common desire that medicine should be a scholarly 
discipline. This presentation explores how theory and practice can 
best be integrated in the education of safe and effective practitioners. 
It draws on theories of training design and observational research 
into how medical students prepare for transition to residency. It aims 
to answer the question “how can medical students best prepare to 
prescribe effectively after starting their careers as doctors”?
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Summary: Up to 60% of depressed patients do not respond com-
pletely to antidepressants (ADs) and up to 30% do not respond at 
all. Genetic factors contribute for ~50% of the AD response. During 
recent years, the possible influence of a set of candidate genes as 
genetic predictors of AD response efficacy was investigated by us 
and others. They include the cytochrome P-450 superfamily, the 
P-glycoprotein (ABCB1), the tryptophan hydroxylase, the catechol-
O-methyltransferase, the monoamine oxidase A, the serotonin trans-
porter (5-HTTLPR), the norepinephrine transporter, the dopamine 
transporter, variants in the 5-hydroxytryptamine receptors (5-HT1A, 
5-HT2A, 5-HT3A, 5-HT3B, and 5-HT6), adrenoreceptor β -1 and 
α -2, the dopamine receptors (D2), the G protein β 3 subunit, the 
corticotropin-releasing hormone receptors (CRHR1 and CRHR2), 
the glucocorticoid receptors, the c-AMP response-element binding, 
and the brain-derived neurotrophic factor. Marginal associations 
were reported for angiotensin I–converting enzyme, circadian loco-
motor output cycles kaput protein, glutamatergic system, nitric oxide 
synthase, and interleukin 1-β gene. In conclusion, gene variants seem 
to influence human behavior, liability to disorders, and treatment 
response. Nonetheless, gene × environment interactions have been 
hypothesized to modulate several of these effects.
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Summary: The advances in genetics and informatics have stimu-
lated research involving biobanks. Research using samples and data 
involves privacy risks. Identifiability and its degrees have implications 
on determining the risk/benefit ratio of a research project. Although 
the need to protect confidentiality and to put in place security meas-
ures is widely recognized, terminological confusion and philosophical 
differences dominate the ethical and legal discussion about confi-
dentiality of data and samples. Different mechanisms, such as cod-
ing or anonymization, influence not only privacy risks of those who 
supplied the biological samples but also determine whether it will 
be possible to communicate the results of any genetic analysis back 
to the research participants. Moreover, it is generally admitted that 
donors have the right to opt out of a biobank. This means that they 
may ask for destruction or unlinked anonymization of samples and 
data. Both can only be carried out if a link is kept between the donors 
and their samples and data.
In this presentation, different strategies of anonymization and 
coding will be described and ethical and legal arguments in favor 
and against them will be discussed, based on the framework of inter-
national ethical guidance and human rights implemented in Europe.
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Summary: The European Network of Centres for 
Pharmacoepidemiology and Pharmacovigilance (ENCePP), coordi-
nated by the European Medicines Agency, has seen rapid growth 
in recent years and now accounts for > 170 partner organizations, 
including research centers, therapeutic networks, and data source 
owners. The increase in pharmacoepidemiology research via net-
works such as ENCePP is a clear trend to make best use of available 
data and expertise, through the conduct of high-quality, independ-
ent, and transparent studies focusing on safety and on benefit/risk. 
Through ENCePP, there is an enhanced capacity to plan and per-
form postauthorization studies that are essential to the monitoring 
of safety and efficacy of medicines throughout the product lifecycle.
In addition to increasing capacity for important observational 
research as requested by regulatory authorities and providing a read-
ily available pool of pharmacoepidemiology expertise, ENCePP has 
been instrumental in developing tools that translate guiding princi-
ples into research practice. The network’s outputs include a Code 
of Conduct, a guide on methodologic research standards, and a 
Checklist for Study Protocols. These are all cited in the recently pub-
lished module VIII of Good Vigilance Practice on PASS. A database 
of studies developed through ENCePP is currently serving as the EU 
PAS Register, where companies register their PASS in compliance 
with the provisions on transparency in the new PhV legislation. 
The EU PAS Register welcomes registration of studies conducted 
worldwide.
Current opportunities for the network include sourcing of sus-
tainable funding for the partner organizations and existing networks 
involved, perceived barriers to sharing of data for studies applying 
for an ENCePP Study Seal, and extension of the network to research 
centers outside of the EU. Overcoming these challenges is important 
to the continued success of the network.
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Summary: Mediator® (benfluorex), a French and worldwide public 
health disaster
Irène Frachon, MD
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Occidentale, Dept de médecine interne et pneumologie, EA 3878, 
IFR 148, Brest, France.
Benfluorex (brand names Mediator®, Mediaxal® , Lipascor®; 
drug company Servier) was marketed in France and worldwide until 
2009. This marketing authorization was held while the  compounds 
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of similar structural and pharmacologic characteristics, such as fen-
fluramine and dexfenfluramine (brand names Ponderal®, Isomeride®; 
Servier, Redux®; Wyeth) have been withdrawn from the world 
market since 1997. Indeed, these compounds, derived from the 
amphetamines, are known to be responsible for pulmonary arterial 
hypertension (PAH) and valvular heart disease (VHD). Subsequent 
studies published in 2000 have shown the determinant role of their 
common active metabolite, norfenfluramine, which is present at 
equal plasma concentrations after fenfluramine, dexfenfluramine, 
or benfluorex intake at recommended dosages. Norfenfluramine 
induces VHD and PAH by stimulation of a serotonin receptor sub-
type, expressed on both aortic and mitral valve leaflets as well as in 
pulmonary arteries.
Despite several case reports stressing the association of PAH 
and/or VHD with benfluorex exposure, benfluorex remained avail-
able in France until November 2009. Our initial case-control study 
published in 2010 put forward the toxicity and the VHD risk of 
benfluorex, thus leading to the withdrawal of benfluorex from the 
European and world market, respectively. This pilot study opened 
the avenue to further pharmacoepidemiologic studies validating 
our results and giving detailed data on the benfluorex risks in larger 
populations.
Actual human consequences of longer than 33 years of marketing 
authorization of benfluorex on patients only in France are estimated 
at ~1300 to 1800 deaths and 3100 to 4200 VHD-related hospitali-
zations. To date, there is no estimation of worldwide mortality due 
to benfluorex use.
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Summary: Recent public discussion on new treatment options in 
orphan diseases has focused on the great promise they hold, as well 
as the high cost they generate for our health systems. Instead, this 
presentation will consider new facts and difficulties arising from these 
treatments from a purely medical standpoint and discuss some of 
them using examples from our daily practice.
Enzyme-replacement therapy (ERT) for certain lysosomal stor-
age disorders (LSD) does not cross the blood-brain barrier (BBB) 
and does not, therefore, influence disease progression in the brain. 
How should we take into account the extent and speed of progress 
of lysosomal brain disease? Even at the peripheral level, definition 
of satisfactory treatment, efficacy is not straightforward. Miglustat, 
an example for substrate reduction therapy, has the advantage to 
cross the BBB. Recently, it has been used in several neuronopathic 
LSD, including early-manifesting Gaucher type III disease. What is 
the impact of inhibiting the synthesis of complex molecules in a brain 
that is still under construction? What benefice can be expected and 
at what age?
Sapropterin (Kuvan®) is a pharmacologic chaperone that has 
recently been introduced for the treatment of phenylketonuria. There 
is, however, a wide interindividual variation of response to this drug; 
it can in only rare instances completely replace the equally or more 
effective dietary treatment. Treatment policies vary among countries 
and even within countries.
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Summary: At least 6 members of the family of the transient receptor 
potential (TRP) channels are expressed in defined subpopulations of 
primary sensory neurons (nociceptors), where they mediate acute 
nociceptive responses and contribute to allodynic and hyperalgesic 
conditions. Most prominent channels are the vanilloid 1 (TRPV1), 
which is activated by capsaicin, protons, and certain eicosanoids, 
and the ankyrin 1 (TRPA1). TRPA1 is uniquely gated by an unprece-
dented series of reactive exogenous (mustard oil, cinnamaldehyde and 
others) and endogenous molecules. These latter molecules include 
byproducts of oxidative stress, as hydrogen peroxide, 4-hydroxynon-
enal, oxononenal, and many others electrophilic agonists, which, 
by binding to key cysteine residues, cause channel activation and 
nociceptor stimulation. All TRPA1-expressing neurons and the 
majority of TRPV1-expressing neurons express and release sensory 
neuropeptides, which mediate neurogenic inflammatory responses. 
Calcitonin gene–related peptide (CGRP) released from perivascu-
lar trigeminal nerve endings upon TRPV1 or TRPA1 stimulation 
has been now recognized as a major contributing factor of migraine 
headaches. A series of agents, known to trigger migraine attacks, 
have been identified as selective stimulants of TRPV1 or TRPA1, 
thereby producing CGRP-dependent meningeal vasodilatation. There 
is growing evidence that TRPV1 and, even at a larger extent, TRPA1 
contribute to thermal and mechanical hypersensitivity in models of 
inflammatory and neuropathic pain. In particular, recent findings 
underscore the critical role of TRPA1 in models of chemotherapeutic-
induced peripheral neuropathy. The desensitizing action on noci-
ceptor function of topical and repeated application of the TRPV1 
agonist, capsaicin, has been used for a long time for the treatment of 
pain in postherpetic neuralgia and in diabetic neuropathy. In contrast, 
clinical development of TRPV1 antagonists has been hampered by 
unexpected evidence obtained in Phase I studies of their ability to 
increase body temperature and heat pain threshold. The underlying 
hypothesis that TRPA1 plays a major role in pain associated with 
increases in oxidative stress is boosting major efforts in the discovery 
and development of TRPA1 antagonists.
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Summary: Knowledge of the driving molecular abnormalities 
that underlie the malignant phenotype has afforded opportunity 
to pharmacologically, and with surgical precision, target cancers. 
Historically, therapy for hematologic malignancies has been associ-
ated with toxicity to normal bone marrow and lymphoid progeni-
tors. This results in myelosuppression and immunosuppression. The 
discovery of the Philadelphia chromosome t (9:22) and subsequent 
clarification that t (9:22)(q34:q11) resulted in the expression of the 
chimeric growth–promoting protein BCR-ABL led to the development 
